Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
RESEARCH TOOLSreports
Holding OLMA?
Track your performance easily
OLMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.51 - $17.79
Previous Close$12.98
Volume1.58M
Average Volume (3M)643.70K
Market Cap
$743.32M
Enterprise Value$506.18M
Total Cash (Recent Filing)$239.10M
Total Debt (Recent Filing)$1.96M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Nov 05, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding57,266,358
10 Day Avg. Volume597,350
30 Day Avg. Volume643,698
Standard Deviation0.29
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.18
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.82
Forecast
1Y Price Target
$28.83Price Target Upside128.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Olema Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial DataUpdated P2 data of palazestrant plus ribociclib in ER+/HER2- advanced/metastatic breast cancer shows a promising clinical benefit rate of 85% across 13 evaluable patients.
Financial PerformanceThe company ended the quarter with a strong financial position, boasting $239.1 million in cash reserves.
Safety And EfficacyNo new safety signals were seen, nor any meaningful impact on drug exposure of either therapy was observed, highlighting the combination's strong safety profile.
Bears Say
EarningsOLMA reported 2Q24 results with a net loss of ($30.4MM), primarily due to increased spending on clinical development activities.
Financial PerformanceOLMA reported 2Q24 results with a net loss of ($30.4MM), primarily due to increased spending on clinical development activities related to palazestrant and advancing the KAT6 inhibitor program.
Market SentimentShort Interest (% Float) 15.0%
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $8.51 and its highest was $17.79 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Currently, no data Available
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Nov 05, 2024 which is in 41 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Aug 06, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.543 by $0.003.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -$0.58.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 57,266,357 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.543. Following the earnings report the stock price went down -9.9%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Among the largest hedge funds holding Olema Pharmaceuticals’s share is Woodline Partners LP. It holds Olema Pharmaceuticals’s shares valued at 9M.
---
Olema Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.83 (128.45% Upside)
$28.83 (128.45% Upside)
Hedge Fund Trend
Increased
By 119.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $35.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.00%
12-Months-Change
Fundamentals
Return on Equity
-56.40%
Trailing 12-Months
Asset Growth
43.31%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
---
OLMA Stock 12 Month Forecast
Average Price Target
$28.83
▲(128.45% Upside)
Technical Analysis
Best Analysts Covering OLMA
1 Year
1 Year Success Rate
13/16 ratings generated profit
1 Year Average Return
+102.71%
reiterated a buy rating 2 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +102.71% per trade.
---